Burden trajectories of stroke attributable to lipid-glucose dysfunction and biomarker validation: evidence from the global burden of disease (GBD) 2023 and the China health and retirement longitudinal study (CHARLS)
ZhenKun Xiao, LiangJie Deng, YongHong Duan, Bing Wang, AiHua Liu · 2026
Read Burden trajectories of stroke attributable to lipid-glucose dysfunction and biomarker validation: evidence from the global burden of disease (GBD) 2023 and the China health and retirement longitudinal study (CHARLS) by ZhenKun Xiao, LiangJie Deng, YongHong Duan, Bing Wang, AiHua Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551825.txt.
Description
ZhenKun Xiao, LiangJie Deng, YongHong Duan, Bing Wang, and AiHua Liu published a 2026 study pairing global burden estimates with individual cohort data on stroke tied to blood sugar and cholesterol dysfunction. Global Burden of Disease figures traced Chinese stroke deaths and disability from high fasting glucose and high LDL cholesterol between 1990 and 2023. A Chinese aging cohort served for discovery, with a United States cohort validating biomarker findings.
Age-standardized death and disability rates fell over the period, yet absolute numbers stayed large in 2023 in the reported estimates. A biomarker called eGDR, reflecting estimated glucose disposal, consistently tied to lower stroke risk and topped the predictor rankings in machine learning analyses. Adding it to standard risk models was tested for discrimination and clinical benefit.
Catalog record
| CREATOR | ZhenKun Xiao, LiangJie Deng, YongHong Duan, Bing Wang, AiHua Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61371 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |